Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Neuroendocrine Tumors
Interventions: PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11; Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Neoplasms
Interventions: GSK2816126; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Skin Appearance, Skin Texture, Skin Sagging, Wrinkles
Interventions: Multi-functional Home-use Beauty Device, Topical Skincare Serum, Skincare Mask; Device · Other
Lead sponsor: APR Co., Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Ischemic Stroke
Interventions: JX10, Placebo; Drug
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Peyronie Disease
Interventions: Collagenase Clostridium Histolyticum, RestoreX, Sildenafil; Drug · Device
Lead sponsor: Charitable Union for the Research and Education of Peyronie's Disease; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Orem, Utah

Conditions: Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
Interventions: BNT141, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • Houston, Texas • San Antonio, Texas

Conditions: Stress
Interventions: MB-Spirit, Strong Behaviors for Stress Reduction; Behavioral
Lead sponsor: Sara W Lazar; Other
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neoplasm Metastasis
Interventions: PF-07265807, Sasanlimab, Axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Obstructive Sleep Apnea
Interventions: Therapeutic HGNS, Subtherapeutic 'Sham' HGNS; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Macular Degeneration
Interventions: BI 754132; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more

Conditions: Tobacco Cessation, Media Use
Interventions: 5A's Model, Media Use Assessment; Other
Lead sponsor: American Academy of Pediatrics; Other
Eligibility: 14 Years to 25 Years
Enrollment: 10,967 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Elk Grove Village, Illinois

Conditions: Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions: Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Gastric Carcinoma
Interventions: Biopsy, Biospecimen Collection, Breath Test, Esophagogastroduodenoscopy, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer Terminal
Interventions: Dignity Therapy - Nurse Led, Usual care, Dignity Therapy - Chaplain Led; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 55 Years and older
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiovascular Health
Interventions: Physical activity coaching; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more

Conditions: Orthopedic Surgery, General Anesthesia
Interventions: vitalHEAT vH2 Temperature Management System, Arizant Healthcare Bair Hugger Temperature Management System; Device
Lead sponsor: Dynatherm Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Advanced-stage Solid Tumors
Interventions: JNJ-89862175; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Boston, Massachusetts • Irving, Texas

Conditions: Superficial, Palpable, Unresectable/Metastatic Solid Tumour
Interventions: AGI-134; Drug
Lead sponsor: Agalimmune Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Morristown, New Jersey • Portland, Oregon

Conditions: Osteoarthritis
Interventions: Exercise and Dietary Weight Loss, Walk with Ease; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years and older
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: tisotumab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: San Jose, California • Fort Collins, Colorado • Miami, Florida + 14 more

Conditions: Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
Interventions: Motivational Interviewing-Based Counseling, Standard Oral Health Education; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 19 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Capecitabine, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
Interventions: healing touch, massage therapy, hypnosis, Standard chemotherapy; Other · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Clinical Evaluation of a Multi-functional Beauty Device on Cosmetic Skin Outcomes

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Assessing MB-Spirit for Psychological Well-being

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Hypoglossal Nerve Stimulation on Cardiovascular Outcomes

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Adolescent Smoking Cessation in Pediatric Primary Care

Effect of Blueberries on Bone Turnover

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Palliative Care for Elderly Outpatients

MyHeart Counts: Stanford Mobile Cardiovascular Health Study 3.0

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Comparison Study of Intraoperative Patient Warming Systems

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Motivational Interviewing to Improve Oral Hygiene in Adolescent Orthodontic Patients

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine